COMMUNIQUÉS West-GlobeNewswire

Alignment Healthcare to Present at William Blair 45th Annual Growth Stock Conference
21/05/2025
ORANGE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, at 2 p.m. [...]
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
21/05/2025
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking strategic partnership [...]
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
21/05/2025
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profile Trial completion expected by Q4 2025 (including a three-month follow-up [...]
Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers
21/05/2025
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the development [...]
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone® IKON à Taiwan
21/05/2025
Le Cyclone ® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV. Louvain-la-Neuve, Belgique, le 21 mai 2025 [...]
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
21/05/2025
The Cyclone ® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – [...]
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
21/05/2025
Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026 Holistic convertible debt restructuring progressing with bondholder [...]
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
21/05/2025
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team capabilities as the business progresses its lead HDAC6 [...]
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants
21/05/2025
Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other [...]
SYNDEO Medical Announces ISO 13485 Certification, Expanding Regulatory Portfolio and Supporting Global Growth Strategy
21/05/2025
ZAVENTEM, Belgium, May 20, 2025 (GLOBE NEWSWIRE) -- SYNDEO Medical, a Belgian-based developer of interventional procedure solutions, is pleased to announce that it has received ISO 13485 certification for its quality [...]
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
20/05/2025
Topline results for AP02 (inhaled nintedanib) confirmed safety and tolerability with limited systemic exposure and substantially improved lung exposure compared to oral nintedanib AP01 (inhaled pirfenidone) treatment [...]
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
20/05/2025
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per [...]
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
20/05/2025
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the [...]
INVO Fertility Announces First Quarter 2025 Financial Results
20/05/2025
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc [...]
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
20/05/2025
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
PCI BIotech: Disclosure of voting rights for Chair of the Board
20/05/2025
Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of [...]
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
20/05/2025
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie
20/05/2025
Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
20/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]

Pages